Posted by Michael Wonder on 29 Jan 2025
FDA approves Ozempic (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
28 January 2025 - The approval is based on the results of the pivotal FLOW Phase 3b kidney outcomes trial and addresses a critical need for adults with type 2 diabetes living with this common comorbidity of chronic kidney disease.
Novo Nordisk today announced that the US FDA has approved Ozempic to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.
